ANL

Adlai Nortye Ltd. ADR

Sep 17 • 04:00PM ET

1.78

-0.01 -0.79 %

Healthcare • Biotechnology • China • NASD

Peers: LLY BMY REGN PFE MRK JNJ AMGN GILD BIIB VRTX

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	27.00M	Perf Week	0.33%
Market Cap	55.48M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-1.29%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	0.19%	Short Float	-	Perf Quarter	2.07%
Income	-	P/S	-	EPS this Y	-	Inst Trans	0.15%	Short Ratio	0.41	Perf Half Y	-24.11%
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.00M	Perf YTD	-33.86%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	3.89 -54.35%	Perf Year	-17.40%
Cash/sh	-	P/FCF	-	EPS past 3/5Y	2.20% -24.39%	ROIC	-	52W Low	1.10 61.45%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.93% 6.46%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	58.47	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	2.68%	Beta	-0.93	Target Price	9.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	9.84%	Rel Volume	3.21	Prev Close	1.79
Employees	123	LT Debt/Eq	-	Earnings	Aug 07	SMA200	-7.54%	Avg Volume	8.21K	Price	1.78
IPO	Sep 29, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	26,312	Change	-0.79%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-04-24	Initiated	H.C. Wainwright	Buy	$9
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$30

Apr-10-25 08:00AM	Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025 (GlobeNewswire)
Aug-08-24 08:30AM	Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress (GlobeNewswire)
08:00AM	Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors (GlobeNewswire)
Jun-04-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-23-24 09:03PM	Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 (GlobeNewswire) -5.65% -12.72%
08:00AM	Loading…
May-22-24 08:00AM	Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy (GlobeNewswire)
May-15-24 09:40AM	Are Medical Stocks Lagging Adlai Nortye Ltd. Sponsored ADR (ANL) This Year? (Zacks) +7.08%
Apr-25-24 09:40AM	Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-29-24 06:00AM	Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development (GlobeNewswire)
Nov-17-23 07:30AM	Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC (GlobeNewswire)
Oct-23-23 08:12AM	Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award (GlobeNewswire)
Oct-03-23 12:05PM	Adlai Nortye Ltd. Announces Closing of Initial Public Offering (GlobeNewswire) -6.87%
Sep-29-23 02:46AM	Adlai Nortye Ltd. Announces Pricing of Initial Public Offering (GlobeNewswire)

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANL

Adlai Nortye Ltd. ADR

Upgrade your FINVIZ experience